Published in N Engl J Med on January 05, 2006
A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants. | NCT00140673
Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia (ROTAVAC) | NCT03602053
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Rethinking global access to vaccines. BMJ (2008) 3.60
Enteric infections, diarrhea, and their impact on function and development. J Clin Invest (2008) 3.23
Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science (2009) 2.67
Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol (2012) 2.65
The promise of new rotavirus vaccines. N Engl J Med (2006) 2.58
Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet (2014) 2.35
Enteropathies in the developing world: neglected effects on global health. Am J Trop Med Hyg (2012) 2.27
Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ (2008) 2.16
Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. J Clin Invest (2013) 2.15
Seasonality of rotavirus disease in the tropics: a systematic review and meta-analysis. Int J Epidemiol (2008) 2.14
Evolutionary history and global spread of the emerging g12 human rotaviruses. J Virol (2006) 2.12
Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis (2009) 2.12
Rotaviruses: from pathogenesis to vaccination. Gastroenterology (2009) 2.05
Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med (2011) 2.04
Neonatal infection with G10P[11] rotavirus did not confer protection against subsequent rotavirus infection in a community cohort in Vellore, South India. J Infect Dis (2007) 1.83
Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med (2011) 1.83
Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol (2010) 1.83
Prevalence of G2P[4] and G12P[6] rotavirus, Bangladesh. Emerg Infect Dis (2007) 1.73
Immunology of gut mucosal vaccines. Immunol Rev (2011) 1.59
Rotavirus vaccines: an overview. Clin Microbiol Rev (2008) 1.58
Gastroenterology in developing countries: issues and advances. World J Gastroenterol (2009) 1.53
Molecular epidemiology of rotavirus diarrhea among children and adults in Nepal: detection of G12 strains with P[6] or P[8] and a G11P[25] strain. J Clin Microbiol (2006) 1.51
Comparative study of the epidemiology of rotavirus in children from a community-based birth cohort and a hospital in South India. J Clin Microbiol (2006) 1.51
Acute gastroenteritis in children. BMJ (2007) 1.50
Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J (2010) 1.48
A threshold method for immunological correlates of protection. BMC Med Res Methodol (2013) 1.41
Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ (2010) 1.39
Performance of rotavirus vaccines in developed and developing countries. Hum Vaccin (2010) 1.39
Emergence of Rotavirus G12P[8] in St. Louis During the 2012-2013 Rotavirus Season. J Pediatric Infect Dis Soc (2014) 1.38
Predominance of rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg Infect Dis (2007) 1.35
Genetic analyses reveal differences in the VP7 and VP4 antigenic epitopes between human rotaviruses circulating in Belgium and rotaviruses in Rotarix and RotaTeq. J Clin Microbiol (2011) 1.33
Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health (2010) 1.31
Incidence and clinical characteristics of group A rotavirus infections among children admitted to hospital in Kilifi, Kenya. PLoS Med (2008) 1.31
Rotavirus diversity and evolution in the post-vaccine world. Discov Med (2012) 1.28
Cost-effectiveness of Rotavirus vaccination in Vietnam. BMC Public Health (2009) 1.27
Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin Infect Dis (2013) 1.23
Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J Virol (2006) 1.22
Immune responses to rotavirus infection and vaccination and associated correlates of protection. J Infect Dis (2011) 1.20
Human rotavirus G9 and G3 as major cause of diarrhea in hospitalized children, Spain. Emerg Infect Dis (2006) 1.20
Differential profiles and inhibitory effect on rotavirus vaccines of nonantibody components in breast milk from mothers in developing and developed countries. Pediatr Infect Dis J (2013) 1.17
The effect of rotavirus vaccine on diarrhoea mortality. Int J Epidemiol (2010) 1.17
Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis. PLoS Med (2012) 1.16
Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. Bull World Health Organ (2014) 1.14
Burden of disease & molecular epidemiology of group A rotavirus infections in India. Indian J Med Res (2007) 1.13
Water, sanitation, hygiene and enteric infections in children. Arch Dis Child (2013) 1.13
Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics (2013) 1.13
Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infect Dis (2012) 1.12
Rotavirus immune responses and correlates of protection. Curr Opin Virol (2012) 1.11
Use of formative research in developing a knowledge translation approach to rotavirus vaccine introduction in developing countries. BMC Public Health (2007) 1.11
Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine (2012) 1.09
The use of cost-effectiveness analysis for pediatric immunization in developing countries. Milbank Q (2012) 1.09
Ovine rotaviruses. Open Vet J (2011) 1.08
Th17 cytokines and vaccine-induced immunity. Semin Immunopathol (2010) 1.07
Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. Pediatrics (2016) 1.07
Rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg Infect Dis (2008) 1.07
Influence of birth rates and transmission rates on the global seasonality of rotavirus incidence. J R Soc Interface (2011) 1.07
Inadequately treated wastewater as a source of human enteric viruses in the environment. Int J Environ Res Public Health (2010) 1.05
The health and economic burden of rotavirus disease in Belgium. Eur J Pediatr (2008) 1.05
Understanding reduced rotavirus vaccine efficacy in low socio-economic settings. PLoS One (2012) 1.05
Nosocomial Rotavirus Gastroenteritis in pediatric patients: a multi-center prospective cohort study. BMC Infect Dis (2010) 1.03
Rotavirus and not age determines gastroenteritis severity in children: a hospital-based study. Eur J Pediatr (2006) 1.03
Genomic analysis of codon, sequence and structural conservation with selective biochemical-structure mapping reveals highly conserved and dynamic structures in rotavirus RNAs with potential cis-acting functions. Nucleic Acids Res (2010) 1.02
Rotavirus vaccines: current status and future considerations. Hum Vaccin Immunother (2014) 1.02
Epidemiology of rotavirus infection among young children with acute diarrhoea in Burkina Faso. BMC Pediatr (2010) 1.01
Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines. Biologics (2010) 1.00
Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch. Vaccine (2012) 1.00
Detection and genotyping of human rotavirus VP4 and VP7 genes by reverse transcriptase PCR and reverse hybridization. J Clin Microbiol (2009) 1.00
Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin Vaccine Immunol (2009) 0.98
Effectiveness of rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis in young children in Connecticut, USA. Vaccine (2010) 0.98
Effectiveness of monovalent rotavirus vaccine in Bolivia: case-control study. BMJ (2013) 0.97
Development of a microtiter plate hybridization-based PCR-enzyme-linked immunosorbent assay for identification of clinically relevant human group A rotavirus G and P genotypes. J Clin Microbiol (2007) 0.97
Vaccination recommendations for Germany. Dtsch Arztebl Int (2011) 0.97
Validation of the modified Vesikari score in children with gastroenteritis in 5 US emergency departments. J Pediatr Gastroenterol Nutr (2013) 0.96
Modification of rotavirus multiplex RT-PCR for the detection of G12 strains based on characterization of emerging G12 rotavirus strains from South India. J Med Virol (2007) 0.96
Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect (2007) 0.96
The influence of CD4+ CD25+ Foxp3+ regulatory T cells on the immune response to rotavirus infection. Vaccine (2008) 0.95
Hospitalizations for intussusception before and after the reintroduction of rotavirus vaccine in the United States. Arch Pediatr Adolesc Med (2012) 0.95
Diagnosis of viral gastroenteritis in children: interpretation of real-time PCR results and relation to clinical symptoms. Eur J Clin Microbiol Infect Dis (2014) 0.95
Symptomatic and subclinical infection with rotavirus P[8]G9, rural Ecuador. Emerg Infect Dis (2007) 0.94
Direct, indirect, total, and overall effectiveness of the rotavirus vaccines for the prevention of gastroenteritis hospitalizations in privately insured US children, 2007-2010. Am J Epidemiol (2014) 0.94
Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world. BMC Med (2011) 0.94
Complications in hospitalized children with acute gastroenteritis caused by rotavirus: a retrospective analysis. Eur J Pediatr (2011) 0.94
A critical literature review of health economic evaluations of rotavirus vaccination. Hum Vaccin Immunother (2013) 0.94
Complete genome sequence analysis of candidate human rotavirus vaccine strains RV3 and 116E. Virology (2010) 0.94
Economic impact of a rotavirus vaccine in Brazil. J Health Popul Nutr (2008) 0.94
Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation. Gut (2007) 0.93
Detection and genetic characterization of group A rotavirus strains circulating among children with acute gastroenteritis in Japan. J Virol (2007) 0.93
Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. Mucosal Immunol (2014) 0.93
Comparison of 2 assays for diagnosing rotavirus and evaluating vaccine effectiveness in children with gastroenteritis. Emerg Infect Dis (2013) 0.93
Molecular characteristics of German G8P[4] rotavirus strain GER1H-09 suggest that a genotyping and subclassification update is required for G8. J Clin Microbiol (2009) 0.92
Rotavirus vaccines: update on global impact and future priorities. Hum Vaccin (2011) 0.92
Changes in childhood diarrhea incidence in nicaragua following 3 years of universal infant rotavirus immunization. Pediatr Infect Dis J (2011) 0.92
Estimates of the economic burden of rotavirus-associated and all-cause diarrhoea in Vellore, India. Trop Med Int Health (2008) 0.92
The ABC of clinical and experimental adjuvants--a brief overview. Immunol Lett (2009) 0.92
Diarrhoea-related hospitalizations in children before and after implementation of monovalent rotavirus vaccination in Mexico. Bull World Health Organ (2013) 0.91
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet (2012) 12.41
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet (2004) 9.24
Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med (2014) 6.58
Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med (2007) 6.54
Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med (2007) 5.87
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med (2015) 4.79
Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg (2003) 4.75
Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med (2011) 4.46
Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. J Infect Dis (2009) 4.25
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med (2015) 4.23
The epidemiology of dengue in the americas over the last three decades: a worrisome reality. Am J Trop Med Hyg (2010) 4.09
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis (2012) 3.94
Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet (2011) 3.12
Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med (2013) 3.09
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med (2004) 2.93
Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J (2006) 2.83
Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis (2009) 2.68
Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J (2012) 2.42
Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J (2011) 2.33
Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J Pediatr (2004) 2.20
Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clin Infect Dis (2006) 2.18
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine (2005) 2.18
Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother (2004) 2.17
Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis (2010) 2.16
Prevalence of pneumococcal disease, serotype distribution, and antimicrobial susceptibility in Mexican children younger than 5 years of age. Arch Med Res (2013) 2.11
Impact of the novel influenza A (H1N1) during the 2009 autumn-winter season in a large hospital setting in Santiago, Chile. Clin Infect Dis (2010) 2.09
Impact of routine fluconazole prophylaxis for premature infants with birth weights of less than 1250 grams in a developing country. Pediatr Infect Dis J (2010) 2.08
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis (2013) 1.95
Imported Lassa fever in Germany: surveillance and management of contact persons. Clin Infect Dis (2003) 1.91
Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis (2012) 1.87
Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis (2011) 1.80
Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin (2009) 1.75
Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine (2008) 1.71
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis (2013) 1.70
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol (2012) 1.70
The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med (2002) 1.70
Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine (2005) 1.68
Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004. Am J Gastroenterol (2008) 1.68
Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg (2003) 1.65
Acute diarrhea in West African children: diverse enteric viruses and a novel parvovirus genus. J Virol (2012) 1.64
Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis (2002) 1.64
Oral prednisolone in the acute management of children age 6 to 35 months with viral respiratory infection-induced lower airway disease: a randomized, placebo-controlled trial. J Pediatr (2003) 1.64
Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population. J Infect Dis (2013) 1.64
Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. J Pediatr (Rio J) (2007) 1.62
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Hum Vaccin (2009) 1.61
Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine (2009) 1.56
Gestural communication of the gorilla (Gorilla gorilla): repertoire, intentionality and possible origins. Anim Cogn (2009) 1.54
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine (2006) 1.48
Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies. Clin Infect Dis (2002) 1.45
Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg (2003) 1.45
Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine (2008) 1.43
A waterborne outbreak of Escherichia coli O157:H7 infections and hemolytic uremic syndrome: implications for rural water systems. Emerg Infect Dis (2002) 1.43
Using reconfigurable hardware to accelerate multiple sequence alignment with ClustalW. Bioinformatics (2005) 1.43
Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg (2003) 1.43
Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg (2008) 1.42
Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine (2010) 1.40
Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study. J Infect Dis (2011) 1.40
[Papillomavirus and cervical cancer in Chile]. Rev Med Chil (2008) 1.39
Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study). Cancer Epidemiol Biomarkers Prev (2011) 1.37
Coibamide A, a potent antiproliferative cyclic depsipeptide from the Panamanian marine cyanobacterium Leptolyngbya sp. J Am Chem Soc (2008) 1.36
[Human papillomavirus vaccine. Statement of the Advisory Committee of Immunizations on behalf of the Chilean Infectious Diseases Society. September 2008]. Rev Med Chil (2008) 1.36
Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J (2007) 1.35
Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine (2005) 1.35
Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J (2005) 1.35